dinoprost and azelastine

dinoprost has been researched along with azelastine* in 1 studies

Other Studies

1 other study(ies) available for dinoprost and azelastine

Article	Year
Azelastine suppresses the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells. Prostaglandins, leukotrienes, and essential fatty acids, 1997, Volume: 56, Issue:3 We investigated the effects of azelastine, an anti-allergic agent, on the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells (HUVEC). High performance liquid chromatography (HPLC) revealed that HUVEC treated with 10(-5) M azelastine released smaller amounts of arachidonic acid metabolites into the medium than control HUVEC. Azelastine significantly reduced the release of prostaglandin F2 alpha (PGF2 alpha), leukotriene B4 (LTB4) and 5-hydroxy-eicosatetraenoic acid (5-HETE) by HUVEC. These results suggest that azelastine may inhibit contraction of bronchial smooth muscle cells and reduce bronchial inflammation by suppressing the release of arachidonic acid metabolites from vascular endothelial cells. Topics: Anti-Allergic Agents; Arachidonic Acid; Bronchoconstriction; Cells, Cultured; Chromatography, High Pressure Liquid; Dinoprost; Endothelium, Vascular; Humans; Hydroxyeicosatetraenoic Acids; Leukotriene B4; Muscle Contraction; Phthalazines; Umbilical Veins	1997

Article

Year

Azelastine suppresses the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells.

Prostaglandins, leukotrienes, and essential fatty acids, 1997, Volume: 56, Issue:3

We investigated the effects of azelastine, an anti-allergic agent, on the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells (HUVEC). High performance liquid chromatography (HPLC) revealed that HUVEC treated with 10(-5) M azelastine released smaller amounts of arachidonic acid metabolites into the medium than control HUVEC. Azelastine significantly reduced the release of prostaglandin F2 alpha (PGF2 alpha), leukotriene B4 (LTB4) and 5-hydroxy-eicosatetraenoic acid (5-HETE) by HUVEC. These results suggest that azelastine may inhibit contraction of bronchial smooth muscle cells and reduce bronchial inflammation by suppressing the release of arachidonic acid metabolites from vascular endothelial cells.

Topics: Anti-Allergic Agents; Arachidonic Acid; Bronchoconstriction; Cells, Cultured; Chromatography, High Pressure Liquid; Dinoprost; Endothelium, Vascular; Humans; Hydroxyeicosatetraenoic Acids; Leukotriene B4; Muscle Contraction; Phthalazines; Umbilical Veins

1997